Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/23641
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Glover, M | - |
dc.contributor.author | Caplin, M | - |
dc.contributor.author | Leeuwenkamp, OR | - |
dc.contributor.author | Longworth, L | - |
dc.date.accessioned | 2021-11-30T10:26:31Z | - |
dc.date.available | 2021-11-30T10:26:31Z | - |
dc.date.issued | 2021-11-09 | - |
dc.identifier.citation | Glover, M., Caplin, M., Leeuwenkamp, O.R. and Longworth, L. (2021) 'Use of [<sup>177</sup>Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study', European Journal of Cancer, Supplement, 16, pp. 14 - 23. doi: 10.1016/j.ejcsup.2021.06.003. | en_US |
dc.identifier.issn | 1359-6349 | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/23641 | - |
dc.description.abstract | Copyright © 2021 The Author(s). Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materials and methods: A three-state partitioned survival model was developed to perform a cost-utility analysis of [177Lu]Lu-DOTA-TATE versus standard of care (high dose Octreotide LAR), everolimus and sunitinib. Effectiveness data for SoC, everolimus and sunitinib were obtained from published Kaplan–Meier survival curves. Given a lack of head-to-head effectiveness data, matching adjusted indirect comparisons (MAICs) were performed to population-adjust [177Lu]Lu-DOTA-TATE survival data based on prognostic factors and derive estimates of relative effectiveness. Health state utilities were estimated from real-world evidence. Drug acquisition costs were taken from nationally published sources (BNF, NICE), and administration costs were based on treatment protocols in [177Lu]Lu-DOTA-TATE studies, combined with nationally published unit costs (PSSRU, DoH reference costs). Incidence of adverse events were estimated using published sources. A discount rate of 3.5% was applied to both utilities and costs, and deterministic and probabilistic sensitivity analyses were performed. Costs were included from an NHS perspective and presented in 2017/18 GBP (and PPP Euros for base case). Results: In GI-NETs, the incremental cost-effectiveness ratio (ICER) of [177Lu]Lu-DOTA-TATE compared to SoC and everolimus was £26,528 (€27,672) and £24,145 (€25,186) per QALY, respectively. In P-NETs, the ICER of [177Lu]Lu-DOTA-TATE compared to SoC was £22,146 (€23,101) or £28,038 (€29,251) dependent on matched population, and £21,827 (€22,766) and £15,768 (€16,445) compared to everolimus and sunitinib, respectively. Conclusions: At a willingness to pay threshold of £30,000, [177Lu]Lu-DOTA-TATE is likely to be a cost-effective treatment option for GI-NET and P-NET patients versus relevant treatment comparators (NHS perspective). | en_US |
dc.description.sponsorship | Advanced Accelerator Applications (AAA), a Novartis company. | en_US |
dc.format.extent | 14 - 23 | - |
dc.format.medium | Print-Electronic | - |
dc.language.iso | en_US | en_US |
dc.rights | © 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-NDlicense (https://creativecommons.org/licenses/by-nc-nd/4.0/) | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.subject | Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs)177 | en_US |
dc.subject | 177-Lu-DOTA-octreotate | en_US |
dc.subject | [177Lu]Lu-DOTA-TATE | en_US |
dc.subject | Everolimus | en_US |
dc.subject | Sunitinib | en_US |
dc.subject | Quality-Adjusted Life Years (QALYs) | en_US |
dc.title | Use of [<sup>177</sup>Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study | en_US |
dc.type | Article | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.ejcsup.2021.06.003 | - |
dc.relation.isPartOf | European Journal of Cancer, Supplement | - |
pubs.publication-status | Published | - |
pubs.volume | 16 | - |
dc.identifier.eissn | 1878-1217 | - |
Appears in Collections: | Dept of Health Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | 1.14 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License